Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.

• Houda, I.
• Dickhoff, C.
• Uyl-de Groot, C. A.
• Damhuis, R. A. M.
• Reguart, N.
• Provencio, M.
• Levy, A.
• Dziadziuszko, R.
• Pompili, C.
• Di Maio, M.
• Thomas, M.
• Brunelli, A.
• Popat, S.
• Senan, S.
• Bahce, I.